ClinicalTrials.gg
RecruitingNCT07306104Updated Apr 29, 2026

The Effect of Long-term Daily Stimulation of the Brain With Pulsed Electromagnetic Fields on Parkinsons Disease

An interventional study of Transcranial pulsed electromagnetic fields (T-PEMF) and Sham (No Treatment) in PARKINSON DISEASE (Disorder), sponsored by University of Southern Denmark. Recruiting at 2 sites in Denmark. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by University of Southern Denmark · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Parkinson Disease with a site in Denmark — 12 open to participants now, 18 under way, 1 of them phase 3. Parkinson Disease · Denmark.

Planned enrollment
16th of 33
90 · median 75
Started
2026
with 1 other
No phase
23 of 50
9 open now
Primary completion
2028-01
later than 12 of 17 live
Registered
45th of 50
by date

Among the 50 studies in Parkinson Disease with a site in Denmark, this one is the 16th largest by planned enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2026, is one of 23 with no phase, reaches primary completion later than 12 of the 17 other live ones, and was the 45th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

12 of the 50 studies in Parkinson Disease with a site in Denmark are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Parkinson Disease with a site in Denmark, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn to what extent daily stimulation of the brain with transcranial pulsed electromagnetic fields (T-PEMF) works to treat persons with Parkinson's Disease. The main questions it aims to answer are:

  • How does 6 months of daily treatment (30 minutes/day) with T-PEMF affects neuro-mechanical and molecular biological factors compared with placebo treatment in persons with Parkinson's disease?
  • How does 12 months of daily treatment (30 minutes/day) with T-PEMF affects neuro-mechanical and molecular biological factors in persons with Parkinson's disease an does 12 months of T-PEMF alters the need for medication intake?

The neuro-mechanical outcomes are compared with the "natural" progression of the disease as well as with a healthy reference group. Furthermore, it will be examined whether 12 months of T-PEMF treatment alters the need for medication intake.

Participants in the intervention group will:

  • receive one 30 min treatment session daily for 12 months
  • receive either T-PEMF or sham treatment for the first 6 months
  • receive active T-PEMF treatment the last 6 months
  • visit for tests before treatment initiation, after 6 months of treatment and after 12 months of treatment.
03

Conditions studied

  • PARKINSON DISEASE (Disorder)

Browse trials for

Keywords

  • T-PEMF
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Intervention Groups

Inclusion Criteria:

  • Diagnosed with idiopathic Parkinson's disease
  • The participant must be able to understand, accept, and complete the planned procedures
  • Parkinson's symptoms in the medicated state must correspond to Hoehn \& Yahr stage 1 or 2
  • Mini Mental-State Examination score > 22

Exclusion Criteria:

  • Cancer in the brain, neck, or head area
  • Presence of active medical implants
  • Epilepsy
  • Alcoholism
  • Substance abuse
  • Open wound on the scalp
  • Severe psychopathological disorders
  • Pregnancy
  • Changes in pharmacological anti-Parkinson medication within the last 6 weeks prior to the start of T-PEMF treatment
  • Anticoagulant treatment with Marevan, Marcoumar, Pradaxa, Eliquis, Xarelto, Lixiana, Novostan, Fragmin, or Innohep
  • Neurological disease other than Parkinson's disease
  • Previous stroke
  • Reduced motor function caused by conditions other than Parkinson's disease

Control Group with Parkinson's Disease

Inclusion Criteria:

  • Diagnosed with idiopathic Parkinson's disease
  • The patient must be able to understand, accept, and complete the planned procedures
  • Parkinson's symptoms in the medicated state must correspond to Hoehn \& Yahr stage 1 or 2
  • Mini Mental-State Examination score > 22

Exclusion Criteria:

  • Neurological disease other than Parkinson's disease
  • Reduced motor function caused by conditions other than Parkinson's disease

Healthy Reference Group:

Inclusion Criteria:

-The patient must be able to understand, accept, and complete the planned procedures

Exclusion Criteria:

  • Neurological disease
  • Reduced motor function caused by condition
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Intervention group 1: Full T-PEMF

    Persons with Parkinson's disease receiving 30 min daily active T-PEMF for 12 months. The first 6 months are blinded, the last 6 months are not.

    Device: Transcranial pulsed electromagnetic fields (T-PEMF)

  • Sham comparator
    Intervention group 2: sham + T-PEMF

    Persons with Parkinson's disease receiving 30 min daily sham T-PEMF for 6 months followed by 6 moths of 30 min daily active T-PEMF. The first 6 month is blinded, the last 6 months are not.

    Device: Transcranial pulsed electromagnetic fields (T-PEMF) · Device: Sham (No Treatment)

  • No intervention
    Control group

    Persons with Parkinson's disease receiving no experimental treatment. The group is used to monitor natural course of the disease.

  • No intervention
    Healthy reference group

    Health age-matched persons assessed once to obtain age-matched normal intervals of performance.

Interventions

  • DeviceTranscranial pulsed electromagnetic fields (T-PEMF)

    30 min daily stimulation with transcranial pulsed electromagnetic fields (50 Hz)

  • DeviceSham (No Treatment)

    30 min daily the participants are using/wearing the T-PEMF device but no stimulation occurs

06

What researchers measure

Primary outcomes

  1. Sit-to-stand

    Completion time of 5 repetition sit-tot-stand test at maximal speed performed on force plate.

    Time frame: From enrollment to end of intervention assessed at baseline, after 6 months and after 12 months.

Secondary outcomes

  1. Tremor intensity

    Postural tremor intensity assessed by accelerometer

    Time frame: From enrollment to end of intervention assessed at baseline, after 6 months and after 12 months.

  2. Rate of force development

    Isometric rate of force development assessed by handgrip and knee extension

    Time frame: From enrollment to end of intervention assessed at baseline, after 6 months and after 12 months.

  3. Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)

    The MDS-UPDRS will be reported as total score (0-260, higher scores indicate greater disease severity) and motor score (part III, 0-132, higher scores indicate greater disease severity).

    Time frame: From enrollment to end of intervention assessed at baseline, after 6 months and after 12 months.

  4. Cerebrospinal fluid biomarkers

    Concentration of growth factors, cytokines and cytoskeletal proteins with special emphasis on erythropoietin (EPO), vascular endothelial growth factor (VEGF), brain-derived neutrophic factor (BDNF), glia cell derived neutrophilic factor (GDNF), Glucagon Like Peptide 1 (GLP1), interleukins and neurofilament light chain (NfL).

    Time frame: From enrollment to end of intervention assessed at baseline, after 6 months and after 12 months. Assessment in the intervention groups only.

Other outcomes

  1. EMG

    Electromyographic recordings of forearm and thigh muscles during motor assessments (sit-to-stand, isometric contractions, postural tremor assessment, handwriting). Applied for explorative analyses, thus exact outcomes are not yet specified. However, agonist drive and co-contraction ratio may be assessed.

    Time frame: From enrollment to end of intervention assessed at baseline, after 6 months and after 12 months.

  2. Hand writing

    Hand writing test performed with ink pen on paper on top of tablet (digitalizing handwriting). Performed as an explorative assessment.

    Time frame: From enrollment to end of intervention assessed at baseline, after 6 months and after 12 months.

07

Study locations

2 of 2 sites recruiting
  • Odense University Hospital
    Odense, 5000, Denmark
    Recruiting
  • University of Southern Denmark
    Odense, 5230, Denmark
    Recruiting
    • Anne Sofie Bøgh Malling, Ph.d. · Contactamalling@health.sdu.dk · +45 28903733
    • Jens Bojsen-Møller, Ass. proffessor · Contactjbojsen@health.sdu.dk
    • Anne Sofie B Malling, Ph.d. · Principal investigator
    • Mikkel C Juhl, MSc · Sub investigator
    • Morten Meyer, Professor · Sub investigator
    • Bente R Jensen, Professor · Sub investigator
    • Jens Bojsen-Møller, Ass. Professor · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jan 2028, 23 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 23 months is close to that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 29, 2025
StartActual
Feb 16, 2026
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07306104
Collaborators
Odense University Hospital, Bente & Erik Schøller Larsens Foundation
Responsible party
Sponsor
First posted
Dec 29, 2025
Start date
Feb 16, 2026
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Apr 29, 2026

Study contacts

Anne Sofie Bøgh Malling, Ph.d.
Contact
amalling@health.sdu.dk
+45 28903733
Bente Rona Jensen, Professor
Contact
brjensen@health.sdu.dk
Anne Sofie Bøgh Malling, Ph.d.
principal investigator · University of Southern Denmark

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion